Evidence map›Paper›PMID 37292469›Full record

ArticleArXiv2023

The evolution of next-generation sequencing technologies.

Olaitan Akintunde, Trichina Tucker, Valerie J Carabetta

Abstract readPreprint
In one paragraph

Article in ArXiv, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Olaitan AkintundeDepartment of Biomedical Sciences, Cooper Medical School of Rowan University, Camden NJ, 08103.
Trichina TuckerDepartment of Biomedical Sciences, Cooper Medical School of Rowan University, Camden NJ, 08103.
Valerie J CarabettaDepartment of Biomedical Sciences, Cooper Medical School of Rowan University, Camden NJ, 08103.

Funding

Investigation of the physiological significance of protein acetylation in Bacillus subtilisR35GM138303 · NIGMS · ROWAN UNIVERSITY · PI CARABETTA, VALERIE JEAN · 2020 to 2024
$1.9M
NIGMS NIH HHS R35 GM138303
6 · The paper itself

Abstract

The genetic information that dictates the structure and function of all life forms is encoded in the DNA. In 1953, Watson and Crick first presented the double helical structure of a DNA molecule. Their findings unearthed the desire to elucidate the exact composition and sequence of DNA molecules. Discoveries and the subsequent development and optimization of techniques that allowed for deciphering the DNA sequence has opened new doors in research, biotech, and healthcare. The application of high-throughput sequencing technologies in these industries has positively impacted and will continue to contribute to the betterment of humanity and the global economy. Improvements, such as the use of radioactive molecules for DNA sequencing to the use of florescent dyes and the implementation of polymerase chain reaction (PCR) for amplification, led to sequencing a few hundred base pairs in days, to automation, where sequencing of thousands of base pairs in hours became possible. Significant advances have been made, but there is still room for improvement. Here, we look at the history and the technology of the currently available high-through put sequencing platforms and the possible applications of such technologies to biomedical research and beyond.

Indexed as

DNA-seqhigh-throughput sequencingNext-generation sequencingRNA-seqsingle-molecule sequencing

Identifiers

PMID37292469
PMCPMC10246072

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.